One study found that RANTES level was significantly higher in patients with AD than in control subjects and was positively correlated with IL-6 and TNF-α levels (43), implying that CCL5 contributes to AD pathogenesis by mediating the inflammatory response and is a potential biomarker for early disease diagnosis. This evidence concerns the gene CCL5 and Alzheimer disease.